JP2007238637A5 - - Google Patents

Download PDF

Info

Publication number
JP2007238637A5
JP2007238637A5 JP2007170267A JP2007170267A JP2007238637A5 JP 2007238637 A5 JP2007238637 A5 JP 2007238637A5 JP 2007170267 A JP2007170267 A JP 2007170267A JP 2007170267 A JP2007170267 A JP 2007170267A JP 2007238637 A5 JP2007238637 A5 JP 2007238637A5
Authority
JP
Japan
Prior art keywords
solid oral
preparation according
oral preparation
compressed solid
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007170267A
Other languages
English (en)
Other versions
JP2007238637A (ja
JP4969338B2 (ja
Filing date
Publication date
Priority claimed from GBGB9613470.5A external-priority patent/GB9613470D0/en
Application filed filed Critical
Publication of JP2007238637A publication Critical patent/JP2007238637A/ja
Publication of JP2007238637A5 publication Critical patent/JP2007238637A5/ja
Application granted granted Critical
Publication of JP4969338B2 publication Critical patent/JP4969338B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Claims (22)

  1. a) バルサルタンもしくは薬学的に許容されるその塩の有効量を含む活性成分;および
    b)固体経口剤形の製造に適当な薬学的に許容される添加剤;
    を含み、
    活性成分が、固体経口剤形の全重量に対し35重量%以上で存在し、かつ、
    活性成分が、40mg、80mg、または160mgのバルサルタンのみからなるか、
    80mgのバルサルタンと12.5mgもしくは25mgのヒドロクロロチアジドのみからなるか、または
    160mgのバルサルタンと12.5mgもしくは25mgのヒドロクロロチアジドのみからなる、乾式圧縮法で製造された圧縮固体経口剤。
  2. 活性成分が45から65重量%存在する、請求項1に記載の圧縮固体経口剤。
  3. 活性成分が50重量%以上存在する、請求項1に記載の圧縮固体経口剤。
  4. 添加剤が結合剤を含む、請求項1から3の何れか1つに記載の圧縮固体経口剤。
  5. 結合剤が、デンプン、微晶質セルロース、ヒドロキシプロピルセルロース、ヒドロキシエチルセルロース、およびヒドロキシプロピルメチルセルロースからなる群から選択される、請求項4に記載の圧縮固体経口剤。
  6. 結合剤が10から45重量%の範囲で存在する、請求項4または5に記載の圧縮固体経口剤。
  7. 結合剤が20から30重量%の範囲で存在する、請求項4または5に記載の圧縮固体経口剤。
  8. 結合剤が微晶質セルロースである、請求項4から7の何れか1つに記載の圧縮固体経口剤。
  9. 結合剤が10から30重量%の微晶質セルロースである、請求項5に記載の圧縮固体経口剤。
  10. 添加剤が滑り剤を含む、請求項1から9の何れか1つに記載の圧縮固体経口剤。
  11. 滑り剤が、コロイド状シリカ、三ケイ酸マグネシウム、顆粒セルロース、デンプン、タルク、および3塩基性リン酸カルシウムからなる群から選択される、請求項10に記載の圧縮固体経口剤。
  12. 滑り剤がコロイド状シリカである、請求項10に記載の圧縮固体経口剤。
  13. 滑り剤が0.1から5重量%存在する、請求項10から12の何れか1つに記載の圧縮固体経口剤。
  14. 添加剤が滑沢剤を含む、請求項1から9の何れか1つに記載の圧縮固体経口剤。
  15. 滑沢剤が、ステアリン酸マグネシウム、ステアリン酸アルミニウム、ステアリン酸カルシウム、PEG 4000−8000、およびタルクからなる群から選択される、請求項14に記載の圧縮固体経口剤。
  16. 滑沢剤がステアリン酸マグネシウムである、請求項14に記載の圧縮固体経口剤。
  17. ステアリン酸マグネシウムが1から5重量%存在する、請求項16に記載の圧縮固体経口剤。
  18. 添加剤が充填剤もしくは希釈剤を含む、請求項1から3の何れか1つに記載の圧縮固体経口剤。
  19. 充填剤もしくは希釈剤が、粉砂糖、圧縮糖(compressible sugar)、デキストレート、デキストリン、デキストロース、ラクトース、マンニトール、マイクロセルロース、顆粒セルロース、ソルビトール、スクロース、およびタルクからなる群から選択される、請求項18に記載の圧縮固体経口剤。
  20. 充填剤もしくは希釈剤が、微晶質セルロース Avicel である、請求項18に記載の圧縮固体経口剤。
  21. 充填剤もしくは希釈剤が15から40重量%の範囲で存在する、請求項18から20の何れか1つに記載の圧縮固体経口剤。
  22. 25〜65kNの圧密力で圧縮することにより製造された、請求項1から21の何れか1つに記載の圧縮固体経口剤。
JP2007170267A 1996-06-27 2007-06-28 バルサルタンの固体経口剤形 Expired - Lifetime JP4969338B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9613470.5 1996-06-27
GBGB9613470.5A GB9613470D0 (en) 1996-06-27 1996-06-27 Small solid oral dosage form

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003014987A Division JP2003231634A (ja) 1996-06-27 2003-01-23 バルサルタンの固体経口剤形

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011270429A Division JP2012051948A (ja) 1996-06-27 2011-12-09 バルサルタンの固体経口剤形

Publications (3)

Publication Number Publication Date
JP2007238637A JP2007238637A (ja) 2007-09-20
JP2007238637A5 true JP2007238637A5 (ja) 2010-04-22
JP4969338B2 JP4969338B2 (ja) 2012-07-04

Family

ID=10795969

Family Applications (5)

Application Number Title Priority Date Filing Date
JP10502269A Pending JP2000506540A (ja) 1996-06-27 1997-06-18 バルサルタンの固体経口剤形
JP2003014987A Withdrawn JP2003231634A (ja) 1996-06-27 2003-01-23 バルサルタンの固体経口剤形
JP2007170267A Expired - Lifetime JP4969338B2 (ja) 1996-06-27 2007-06-28 バルサルタンの固体経口剤形
JP2011270429A Withdrawn JP2012051948A (ja) 1996-06-27 2011-12-09 バルサルタンの固体経口剤形
JP2013221985A Pending JP2014012747A (ja) 1996-06-27 2013-10-25 バルサルタンの固体経口剤形

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP10502269A Pending JP2000506540A (ja) 1996-06-27 1997-06-18 バルサルタンの固体経口剤形
JP2003014987A Withdrawn JP2003231634A (ja) 1996-06-27 2003-01-23 バルサルタンの固体経口剤形

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011270429A Withdrawn JP2012051948A (ja) 1996-06-27 2011-12-09 バルサルタンの固体経口剤形
JP2013221985A Pending JP2014012747A (ja) 1996-06-27 2013-10-25 バルサルタンの固体経口剤形

Country Status (33)

Country Link
US (3) US6294197B1 (ja)
EP (7) EP1776953A1 (ja)
JP (5) JP2000506540A (ja)
KR (6) KR100792389B1 (ja)
CN (3) CN1951372B (ja)
AR (2) AR008618A1 (ja)
AT (3) ATE371449T1 (ja)
BR (1) BR9709956A (ja)
CA (2) CA2259148C (ja)
CO (1) CO4870755A1 (ja)
CY (1) CY2553B1 (ja)
CZ (1) CZ296850B6 (ja)
DE (3) DE69738089T2 (ja)
DK (3) DK0914119T3 (ja)
ES (3) ES2231873T3 (ja)
GB (1) GB9613470D0 (ja)
HK (2) HK1019858A1 (ja)
HU (1) HU229134B1 (ja)
ID (1) ID17553A (ja)
IL (2) IL127564A0 (ja)
MY (3) MY123149A (ja)
NO (2) NO317181B1 (ja)
NZ (2) NZ333385A (ja)
PE (1) PE87498A1 (ja)
PL (2) PL188233B1 (ja)
PT (3) PT1410797E (ja)
RU (5) RU2203054C2 (ja)
SI (2) SI1410797T1 (ja)
SK (1) SK285902B6 (ja)
TR (1) TR199802698T2 (ja)
TW (1) TW473394B (ja)
WO (1) WO1997049394A2 (ja)
ZA (1) ZA975673B (ja)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US20030045561A1 (en) * 2001-02-06 2003-03-06 Smithkline Beecham Corporation Method of treating isolated systolic hypertension
BR9908474A (pt) * 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
DK1736144T3 (en) * 1998-05-18 2015-12-07 Takeda Pharmaceutical Orally disintegrating tablets.
SK285863B6 (sk) * 1998-07-10 2007-10-04 Novartis Ag Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín
WO2000038676A1 (en) 1998-12-23 2000-07-06 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
CA2360691A1 (en) * 1999-01-26 2000-08-03 Novartis Ag Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
EP1872797A3 (en) * 1999-08-24 2008-04-02 Medicure International Inc. Treatment of cardiovascular and related pathologies
DE10014416B4 (de) * 2000-03-24 2009-02-19 3M Espe Ag Verwendung feinkörniger Pulver bzw. Pulvergemische zur Herstellung eines Mittels für supragingivales Pulverstrahlen
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
BR0111868A (pt) * 2000-06-22 2003-07-01 Novartis Ag Composições farmacêuticas
AU2005200815B2 (en) * 2000-06-22 2008-01-17 Novartis Ag Solid valsartan pharmaceutical compositions
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
CA2415962C (en) 2000-07-19 2010-07-06 Novartis Ag Valsartan salts
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
CA2519490A1 (en) * 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd Polymorphis of valsartan
US7199144B2 (en) * 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
WO2004094392A1 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan
EP1556363A2 (en) * 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Process for the preparation of valsartan and intermediates thereof
JP4505859B2 (ja) * 2003-08-08 2010-07-21 味の素株式会社 ナテグリニド含有製剤
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
EA008063B1 (ru) * 2003-11-03 2007-02-27 Зентива А.С. Рецептура, содержащая валсартан (valsartan)
JP2005187793A (ja) * 2003-12-24 2005-07-14 Rohm & Haas Electronic Materials Llc 改良された接着剤
WO2005082329A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
CN1976926A (zh) 2004-09-02 2007-06-06 特瓦制药工业有限公司 奥美沙坦酯的制备
ES2523796T1 (es) 2004-10-08 2014-12-01 Forward Pharma A/S Composición farmacéutica de liberación controlada que comprende éster de ácido fumárico
DE602005023193D1 (de) * 2004-10-15 2010-10-07 Suedzucker Ag Verbessertes trommelcoating-verfahren
EP2033629B1 (en) * 2004-12-24 2012-11-14 Krka Solid pharmaceutical composition comprising valsartan
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
EP1982711A1 (en) * 2005-05-31 2008-10-22 Mylan Laboratories, Inc Compositions comprsing nebivolol
WO2007005967A2 (en) * 2005-07-05 2007-01-11 Teva Pharmaceutical Industries Ltd. Process for preparing valsartan
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
WO2007052307A2 (en) * 2005-10-31 2007-05-10 Lupin Limited Stable solid oral dosage forms of valsartan
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EP2007385A4 (en) * 2006-03-23 2010-08-18 Sinai School Medicine CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
US9308259B2 (en) 2006-06-06 2016-04-12 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
KR100963389B1 (ko) * 2006-10-30 2010-06-14 한올바이오파마주식회사 시간차로 방출되는 치아자이드계 화합물과 안지오텐신―ⅱ―수용체 차단제를 포함하는 약학적 조성물
WO2008064338A2 (en) * 2006-11-22 2008-05-29 Rubicon Research Pvt. Ltd. Valsartan formulation for pulsatile delivery
WO2008120242A1 (en) * 2007-03-29 2008-10-09 Alembic Limited Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
US20100273873A1 (en) * 2007-07-31 2010-10-28 Katleen Rosa Francois Brys Direct compressible dextrose
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
MX2010003441A (es) * 2007-09-28 2010-04-21 Novartis Ag Formulaciones galenicas de alisquireno y valsartan.
EP2197416A1 (en) * 2007-10-09 2010-06-23 Novartis Ag Pharmaceutical formulation of valsartan
FI3067043T3 (fi) * 2007-11-06 2023-03-18 Novartis Ag Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
BRPI0821455A2 (pt) * 2007-12-31 2015-06-16 Lupin Ltd Composições farmacêuticas de amlopidina e valsartan
MX2010009500A (es) * 2008-02-28 2010-09-24 Novartis Ag Formas de dosificacion oral solidas de valsartan y metodos para hacer estas formulaciones.
US20090226516A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Sartan compositions
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
US20110117194A1 (en) * 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
AU2009257174A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
KR101033975B1 (ko) * 2008-10-10 2011-05-11 이희엽 직접압축법을 이용한 발사르탄 함유 고형 경구 제형의 제조방법 및 이에 따라 제조된 고형 경구 제형
DE102008051783A1 (de) * 2008-10-17 2010-04-22 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Valsartan enthaltende Tablette
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
EP2405899A2 (en) 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
KR101084783B1 (ko) * 2009-09-01 2011-11-22 삼성에스디아이 주식회사 이차 전지 및 그의 제조 방법
WO2011027021A1 (en) * 2009-09-01 2011-03-10 Orion Corporation A method for the treatment of hypertension
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CN101897675B (zh) * 2010-02-10 2012-11-21 温士顿医药股份有限公司 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
EP2536396B1 (en) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
JP5882796B2 (ja) 2011-03-31 2016-03-09 キヤノン株式会社 振動体の駆動方法、振動装置、該振動装置を有する駆動装置、及び光学機器
GB201116993D0 (en) * 2011-10-03 2011-11-16 Ems Sa Pharmaceutical compositions of antihypertensives
EP2797580A2 (en) 2011-12-26 2014-11-05 Novartis AG Tablets and dry-coated agents
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンii受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
KR101944085B1 (ko) * 2012-09-06 2019-01-30 한국콜마주식회사 발사르탄 함유 고형 경구제형 및 그 제조방법
JP2014062064A (ja) * 2012-09-21 2014-04-10 Ohara Yakuhin Kogyo Kk バルサルタン含有錠剤の製造方法
JP6238831B2 (ja) * 2014-04-25 2017-11-29 沢井製薬株式会社 バルサルタン含有錠剤及びその製造方法
JP6141472B2 (ja) * 2016-03-02 2017-06-07 大原薬品工業株式会社 バルサルタン含有錠剤の製造方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3807898A1 (en) 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200039A (en) 1962-05-28 1965-08-10 Pfizer & Co C Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu
GB1422176A (en) 1973-05-05 1976-01-21 Beecham Group Ltd Pharmaceutical tablets
AU528098B2 (en) 1978-11-16 1983-04-14 Beecham Group Plc Analgesic tablet
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4238485A (en) * 1979-10-29 1980-12-09 Merck & Co., Inc. Novel pharmaceutical compositions
EP0070127A3 (en) 1981-07-10 1983-08-17 Beecham Group Plc Tablets
US4543359A (en) * 1982-10-01 1985-09-24 Eaton Laboratories, Inc. Treating cardiac arrhythmias with dantrolene sodium
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4743612A (en) * 1986-10-17 1988-05-10 Berlex Laboratories, Inc. Prodrug derivatives of the cardiotonic agent 4-ethyl-1,3-dihydro-5-(4-(2-methyl-1H-imidazol-1-yl)benzoyl)-2H-imidazol-2-one, composition containing them, and method of using them to treat cardiac failure
DE3705055A1 (de) * 1987-02-18 1988-09-01 Boehringer Ingelheim Kg Verwendung von 2-(3-fluor-4-methylphenylimino)-imidazolidin zur behandlung der koronaren herzkrankheit
JP2518854B2 (ja) * 1987-06-19 1996-07-31 旭化成工業株式会社 固形製剤の製法
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
SE506179C2 (sv) 1989-01-23 1997-11-17 Ciba Geigy Ag Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
PH30484A (en) * 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
EP0550689A1 (en) * 1990-09-28 1993-07-14 Merck & Co. Inc. Ibuprofen-diuretic combinations
JP3069458B2 (ja) * 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
ZA931063B (en) 1992-02-17 1993-09-23 Ciba Geigy Treatment of glaucoma.
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
WO1994009778A1 (en) 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
WO1994015643A1 (en) 1992-12-30 1994-07-21 Fmc Corporation Readily available konjac glucomannan sustained release excipient
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンii介在性諸疾患の予防または治療剤
US5464854A (en) 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
AT401871B (de) * 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
JP3534130B2 (ja) * 1994-03-01 2004-06-07 旭化成ケミカルズ株式会社 医薬品組成物
GB9404010D0 (en) * 1994-03-02 1994-04-20 Opt Tel Services Limited Telephone dialling monitoring and route selecting apparatus
CN1143908A (zh) 1994-03-17 1997-02-26 西巴-盖尔基股份公司 利用哇尔沙通(valsartan)治疗糖尿病型肾病
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE19502065C2 (de) * 1995-01-14 1996-05-02 Prophyta Biolog Pflanzenschutz Pilzisolat mit fungizider Wirkung
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
JP2011123241A (ja) * 2009-12-10 2011-06-23 Canon Inc 撮影システム

Similar Documents

Publication Publication Date Title
JP2007238637A5 (ja)
JP2003231634A5 (ja)
JP2011037832A5 (ja)
JP2018507200A5 (ja)
HRP20161262T1 (hr) Tablete ulipristal acetata
HRP20140780T4 (hr) Amorfni i kristalinični oblik genz 112638 hemitartrata kao inhibitor glukozilceramid sintaze
JP2007523210A5 (ja)
JP2010132654A5 (ja)
FI3067043T3 (fi) Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia
JP2009537478A5 (ja)
JP2010047612A5 (ja)
JP2006077018A5 (ja)
JP2008501025A5 (ja)
SG10201407947WA (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
JP2018162255A5 (ja)
JP2010536849A5 (ja)
JP2009537554A5 (ja)
MX2012015091A (es) Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol- 2-il]-1h-quinolin-2-ona.
JP2008515980A5 (ja)
JP2011026335A5 (ja)
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
IL305908A (en) Orodispersible tablets containing corticosteroid compositions for eosinophilic esophagitis
JP2006514100A5 (ja)
JP2008534563A5 (ja)
JP2011500811A5 (ja)